메뉴 건너뛰기




Volumn 19, Issue 4, 2012, Pages 313-318

Minimal residual disease monitoring in childhood acute lymphoblastic leukemia

Author keywords

acute lymphoblastic leukemia; flow cytometry; minimal residual disease; polymerase chain reaction; prognosis; remission

Indexed keywords

ASPARAGINASE; CD11B ANTIGEN; CD20 ANTIBODY; CD34 ANTIBODY; CD45 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DAUNORUBICIN; LYMPHOCYTE ANTIGEN RECEPTOR; METHOTREXATE; PREDNISONE; VINCRISTINE;

EID: 84862130973     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283543d5c     Document Type: Review
Times cited : (84)

References (60)
  • 1
    • 79955005365 scopus 로고    scopus 로고
    • Minimal residual disease in acute lymphoblastic leukemia
    • Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2010; 2010:7-12.
    • (2010) Hematol Am Soc Hematol Educ Program , vol.2010 , pp. 7-12
    • Campana, D.1
  • 2
    • 65649143517 scopus 로고    scopus 로고
    • MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR
    • van der Velden VH, van Dongen JJ. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol 2009; 538:115-150.
    • (2009) Methods Mol Biol , vol.538 , pp. 115-150
    • Van Der Velden, V.H.1    Van Dongen, J.J.2
  • 3
    • 78649506177 scopus 로고    scopus 로고
    • Immunologic minimal residual disease detection in acute lymphoblastic leukemia: A comparative approach to molecular testing
    • Coustan-Smith E, Campana D. Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing. Best Pract Res Clin Haematol 2010; 23:347-358.
    • (2010) Best Pract Res Clin Haematol , vol.23 , pp. 347-358
    • Coustan-Smith, E.1    Campana, D.2
  • 4
    • 77949424466 scopus 로고    scopus 로고
    • Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel Germany 18-20 September 2008
    • Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24:521-535.
    • (2010) Leukemia , vol.24 , pp. 521-535
    • Bruggemann, M.1    Schrauder, A.2    Raff, T.3
  • 5
    • 77954727839 scopus 로고    scopus 로고
    • Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia
    • Stow P, Key L, Chen X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010; 115:4657-4663.
    • (2010) Blood , vol.115 , pp. 4657-4663
    • Stow, P.1    Key, L.2    Chen, X.3
  • 6
    • 77954601328 scopus 로고    scopus 로고
    • Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing
    • Boyd SD, Marshall EL, Merker JD, et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med 2009; 1:12ra23.
    • (2009) Sci Transl Med , vol.1
    • Boyd, S.D.1    Marshall, E.L.2    Merker, J.D.3
  • 7
    • 84873069356 scopus 로고    scopus 로고
    • Highly sensitive detection of minimal residual disease in acute lymphoblastic leukemia using next-generation sequencing of immunoglobulin heavy chain variable region
    • Faham M, Willis T, Moorhead M, et al. Highly sensitive detection of minimal residual disease in acute lymphoblastic leukemia using next-generation sequencing of immunoglobulin heavy chain variable region. Blood 2011; 118: 1089-1090.
    • (2011) Blood , vol.118 , pp. 1089-1090
    • Faham, M.1    Willis, T.2    Moorhead, M.3
  • 8
    • 0032770146 scopus 로고    scopus 로고
    • Detection of minimal residual disease in acute leukemia by flow cytometry
    • DOI 10.1002/(SICI)1097-0320(19990815)38:4<139::AID-CYTO1>3.0.CO;2-H
    • Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38:139-152. (Pubitemid 29390417)
    • (1999) Communications in Clinical Cytometry , vol.38 , Issue.4 , pp. 139-152
    • Campana, D.1    Coustan-Smith, E.2
  • 10
    • 66249133415 scopus 로고    scopus 로고
    • Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: Potential usefulness in minimal residual disease detection
    • DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection. Cytometry B Clin Cytom 2009; 76:150-155.
    • (2009) Cytometry B Clin Cytom , vol.76 , pp. 150-155
    • Digiuseppe, J.A.1    Fuller, S.G.2    Borowitz, M.J.3
  • 11
    • 0035313156 scopus 로고    scopus 로고
    • Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia
    • DOI 10.1182/blood.V97.7.2115
    • Chen JS, Coustan-Smith E, Suzuki T, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001; 97:2115-2120. (Pubitemid 32239094)
    • (2001) Blood , vol.97 , Issue.7 , pp. 2115-2120
    • Chen, J.-S.1    Coustan-Smith, E.2    Suzuki, T.3    Neale, G.A.4    Mihara, K.5    Pui, C.-H.6    Campana, D.7
  • 12
    • 79959450187 scopus 로고    scopus 로고
    • New markers for minimal residual disease detection in acute lymphoblastic leukemia
    • Coustan-Smith E, Song G, Clark C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011; 117:6267-6276.
    • (2011) Blood , vol.117 , pp. 6267-6276
    • Coustan-Smith, E.1    Song, G.2    Clark, C.3
  • 13
    • 83855162770 scopus 로고    scopus 로고
    • CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry
    • Solly F, Angelot F, Garand R, et al. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. Cytometry A 2012; 81:17-24.
    • (2012) Cytometry A , vol.81 , pp. 17-24
    • Solly, F.1    Angelot, F.2    Garand, R.3
  • 14
    • 67650718769 scopus 로고    scopus 로고
    • Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia
    • Djokic M, Bjorklund E, Blennow E, et al. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica 2009; 94:1016-1019.
    • (2009) Haematologica , vol.94 , pp. 1016-1019
    • Djokic, M.1    Bjorklund, E.2    Blennow, E.3
  • 15
    • 70449721037 scopus 로고    scopus 로고
    • Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: Utility in detection of minimal residual disease by flow cytometry
    • Muzzafar T, Medeiros LJ, Wang SA, et al. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry. Am J Clin Pathol 2009; 132:692-698.
    • (2009) Am J Clin Pathol , vol.132 , pp. 692-698
    • Muzzafar, T.1    Medeiros, L.J.2    Wang, S.A.3
  • 16
    • 77952570617 scopus 로고    scopus 로고
    • CD11b is a therapy resistance and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia
    • Rhein P, Mitlohner R, Basso G, et al. CD11b is a therapy resistance and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. Blood 2010; 115:3763-3771.
    • (2010) Blood , vol.115 , pp. 3763-3771
    • Rhein, P.1    Mitlohner, R.2    Basso, G.3
  • 17
    • 56749104572 scopus 로고    scopus 로고
    • A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders
    • Pedreira CE, Costa ES, Almeida J, et al. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders. Cytometry A 2008; 73A:1141-1150.
    • (2008) Cytometry A , vol.73 A , pp. 1141-1150
    • Pedreira, C.E.1    Costa, E.S.2    Almeida, J.3
  • 18
    • 83855162815 scopus 로고    scopus 로고
    • Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data
    • Fiser K, Sieger T, Schumich A, et al. Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data. Cytometry A 2012; 81:25-34.
    • (2012) Cytometry A , vol.81 , pp. 25-34
    • Fiser, K.1    Sieger, T.2    Schumich, A.3
  • 20
    • 77952630014 scopus 로고    scopus 로고
    • Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug-induced regulatory phenomenon
    • Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group
    • Dworzak MN, Gaipa G, Schumich A, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom 2010; 78:147-153.
    • (2010) Cytometry B Clin Cytom , vol.78 , pp. 147-153
    • Dworzak, M.N.1    Gaipa, G.2    Schumich, A.3
  • 21
    • 84856229635 scopus 로고    scopus 로고
    • A new method for high speed, sensitive detection of minimal residual disease
    • Liu X, Hsieh HB, Campana D, Bruce RH. A new method for high speed, sensitive detection of minimal residual disease. Cytometry A 2012; 81:169-175.
    • (2012) Cytometry A , vol.81 , pp. 169-175
    • Liu, X.1    Hsieh, H.B.2    Campana, D.3    Bruce, R.H.4
  • 22
    • 47049093795 scopus 로고    scopus 로고
    • Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors. A Children's Oncology Group study
    • Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors. a Children's Oncology Group study. Blood 2008; 111:5477-5485.
    • (2008) Blood , vol.111 , pp. 5477-5485
    • Borowitz, M.J.1    Devidas, M.2    Hunger, S.P.3
  • 23
    • 70449711125 scopus 로고    scopus 로고
    • Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow
    • Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009; 27:5168-5174.
    • (2009) J Clin Oncol , vol.27 , pp. 5168-5174
    • Basso, G.1    Veltroni, M.2    Valsecchi, M.G.3
  • 24
    • 67649410242 scopus 로고    scopus 로고
    • Treating childhood acute lymphoblastic leukemia without cranial irradiation
    • Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360:2730-2741.
    • (2009) N Engl J Med , vol.360 , pp. 2730-2741
    • Pui, C.H.1    Campana, D.2    Pei, D.3
  • 25
    • 66749117163 scopus 로고    scopus 로고
    • Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multicenter setting
    • Irving J, Jesson J, Virgo P, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multicenter setting. Haematologica 2009; 94:870-874.
    • (2009) Haematologica , vol.94 , pp. 870-874
    • Irving, J.1    Jesson, J.2    Virgo, P.3
  • 26
    • 78349293365 scopus 로고    scopus 로고
    • Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia
    • Luria D, Rosenthal E, Steinberg D, et al. Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia. Cytometry B Clin Cytom 2010; 78:365-371.
    • (2010) Cytometry B Clin Cytom , vol.78 , pp. 365-371
    • Luria, D.1    Rosenthal, E.2    Steinberg, D.3
  • 27
    • 73349090614 scopus 로고    scopus 로고
    • Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry
    • Mejstrikova E, Fronkova E, Kalina T, et al. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry. Pediatr Blood Cancer 2010; 54:62-70.
    • (2010) Pediatr Blood Cancer , vol.54 , pp. 62-70
    • Mejstrikova, E.1    Fronkova, E.2    Kalina, T.3
  • 28
    • 0027976273 scopus 로고
    • Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction
    • Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343:196-200.
    • (1994) Lancet , vol.343 , pp. 196-200
    • Brisco, M.J.1    Condon, J.2    Hughes, E.3
  • 32
    • 0034667685 scopus 로고    scopus 로고
    • Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
    • Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96:2691-2696.
    • (2000) Blood , vol.96 , pp. 2691-2696
    • Coustan-Smith, E.1    Sancho, J.2    Hancock, M.L.3
  • 34
    • 0037085750 scopus 로고    scopus 로고
    • Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia
    • DOI 10.1182/blood.V99.6.1952
    • DworzakMN, Froschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99:1952-1958. (Pubitemid 34525474)
    • (2002) Blood , vol.99 , Issue.6 , pp. 1952-1958
    • Dworzak, M.N.1    Froschl, G.2    Printz, D.3    Mann, G.4    Potschger, U.5    Muhlegger, N.6    Fritsch, G.7    Gadner, H.8
  • 36
    • 67650478894 scopus 로고    scopus 로고
    • Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia
    • Sutton R, Venn NC, Tolisano J, et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol 2009; 146:292-299.
    • (2009) Br J Haematol , vol.146 , pp. 292-299
    • Sutton, R.1    Venn, N.C.2    Tolisano, J.3
  • 37
    • 77951441599 scopus 로고    scopus 로고
    • Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study
    • Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115:3206-3214.
    • (2010) Blood , vol.115 , pp. 3206-3214
    • Conter, V.1    Bartram, C.R.2    Valsecchi, M.G.3
  • 38
    • 78049300632 scopus 로고    scopus 로고
    • Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: A report from the Japanese Childhood Cancer and Leukemia Study Group
    • Yamaji K, Okamoto T, Yokota S, et al. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer 2010; 55:1287-1295.
    • (2010) Pediatr Blood Cancer , vol.55 , pp. 1287-1295
    • Yamaji, K.1    Okamoto, T.2    Yokota, S.3
  • 39
    • 77951787638 scopus 로고    scopus 로고
    • Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit
    • Katsibardi K, Moschovi MA, Braoudaki M, et al. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit. Leuk Lymphoma 2010; 51:846-852.
    • (2010) Leuk Lymphoma , vol.51 , pp. 846-852
    • Katsibardi, K.1    Moschovi, M.A.2    Braoudaki, M.3
  • 40
    • 80052079740 scopus 로고    scopus 로고
    • Prognostic value of MRDdynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols
    • Meleshko AN, Savva NN, Fedasenka UU, et al. Prognostic value of MRDdynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols. Leuk Res 2011; 35:1312-1320.
    • (2011) Leuk Res , vol.35 , pp. 1312-1320
    • Meleshko, A.N.1    Savva, N.N.2    Fedasenka, U.U.3
  • 43
    • 57849085208 scopus 로고    scopus 로고
    • Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia
    • Paganin M, Zecca M, Fabbri G, et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia 2008; 22:2193-2200.
    • (2008) Leukemia , vol.22 , pp. 2193-2200
    • Paganin, M.1    Zecca, M.2    Fabbri, G.3
  • 44
    • 50549083190 scopus 로고    scopus 로고
    • Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma
    • Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma. J Clin Oncol 2008; 26:3971-3978.
    • (2008) J Clin Oncol , vol.26 , pp. 3971-3978
    • Raetz, E.A.1    Borowitz, M.J.2    Devidas, M.3
  • 46
    • 58549091682 scopus 로고    scopus 로고
    • Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: The ALL-REZ BFM Study Group
    • Bader P, Kreyenberg H, Henze GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009; 27:377-384.
    • (2009) J Clin Oncol , vol.27 , pp. 377-384
    • Bader, P.1    Kreyenberg, H.2    Henze, G.H.3
  • 47
    • 79960495326 scopus 로고    scopus 로고
    • High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia
    • Leung W, Campana D, Yang J, et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011; 118:223-230.
    • (2011) Blood , vol.118 , pp. 223-230
    • Leung, W.1    Campana, D.2    Yang, J.3
  • 48
    • 84857365039 scopus 로고    scopus 로고
    • Monitoring MRD with flow cytometry: An effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation
    • Zhao XS, Liu YR, Zhu HH, et al. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2012; 91:183-192.
    • (2012) Ann Hematol , vol.91 , pp. 183-192
    • Zhao, X.S.1    Liu, Y.R.2    Zhu, H.H.3
  • 49
    • 80052172961 scopus 로고    scopus 로고
    • Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study
    • Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118:2077-2084.
    • (2011) Blood , vol.118 , pp. 2077-2084
    • Schrappe, M.1    Valsecchi, M.G.2    Bartram, C.R.3
  • 50
    • 67349225042 scopus 로고    scopus 로고
    • Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
    • van der Velden V, Corral L, Valsecchi MG, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009; 23:1073-1079.
    • (2009) Leukemia , vol.23 , pp. 1073-1079
    • Van Der Velden, V.1    Corral, L.2    Valsecchi, M.G.3
  • 51
    • 79961191931 scopus 로고    scopus 로고
    • Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906
    • Bowman WP, Larsen EL, Devidas M, et al. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. Pediatr Blood Cancer 2011; 57:569-577.
    • (2011) Pediatr Blood Cancer , vol.57 , pp. 569-577
    • Bowman, W.P.1    Larsen, E.L.2    Devidas, M.3
  • 52
    • 33745622137 scopus 로고    scopus 로고
    • A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome
    • DOI 10.1182/blood-2006-01-0066
    • Coustan-Smith E, Ribeiro RC, Stow P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006; 108:97-102. (Pubitemid 43990616)
    • (2006) Blood , vol.108 , Issue.1 , pp. 97-102
    • Coustan-Smith, E.1    Ribeiro, R.C.2    Stow, P.3    Zhou, Y.4    Pui, C.-H.5    Rivera, G.K.6    Pedrosa, F.7    Campana, D.8
  • 53
    • 79951804790 scopus 로고    scopus 로고
    • Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia
    • Koh KN, Park M, Kim BE, et al. Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia. Korean J Pediatr 2010; 53:957-964.
    • (2010) Korean J Pediatr , vol.53 , pp. 957-964
    • Koh, K.N.1    Park, M.2    Kim, B.E.3
  • 54
    • 77955714137 scopus 로고    scopus 로고
    • Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation
    • Lankester AC, Bierings MB, Van Wering ER, et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia 2010; 24:1462-1469.
    • (2010) Leukemia , vol.24 , pp. 1462-1469
    • Lankester, A.C.1    Bierings, M.B.2    Van Wering, E.R.3
  • 55
    • 58749109707 scopus 로고    scopus 로고
    • Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia
    • Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360:470-480.
    • (2009) N Engl J Med , vol.360 , pp. 470-480
    • Mullighan, C.G.1    Su, X.2    Zhang, J.3
  • 56
    • 58749095816 scopus 로고    scopus 로고
    • Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia
    • Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10:147-156.
    • (2009) Lancet Oncol , vol.10 , pp. 147-156
    • Coustan-Smith, E.1    Mullighan, C.G.2    Onciu, M.3
  • 57
    • 84862127741 scopus 로고    scopus 로고
    • Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia
    • doi:10.1002/pbc.23395 [Epub ahead of print]
    • Rabin KR, Gramatges MM, Borowitz MJ, et al. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011. doi:10.1002/pbc.23395. [Epub ahead of print]
    • (2011) Pediatr Blood Cancer
    • Rabin, K.R.1    Gramatges, M.M.2    Borowitz, M.J.3
  • 58
    • 79952362834 scopus 로고    scopus 로고
    • In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia
    • Lonnerholm G, Thorn I, Sundstrom C, et al. In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia. Leuk Res 2011; 35:472-478.
    • Leuk Res 2011 , vol.35 , pp. 472-478
    • Lonnerholm, G.1    Thorn, I.2    Sundstrom, C.3
  • 59
    • 79751538993 scopus 로고    scopus 로고
    • Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia
    • Waanders E, van der Velden VH, van der Schoot CE, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011; 25:254-258.
    • (2011) Leukemia , vol.25 , pp. 254-258
    • Waanders, E.1    Van Der Velden, V.H.2    Van Der Schoot, C.E.3
  • 60
    • 79959312575 scopus 로고    scopus 로고
    • Targeted therapy with the T-cellengaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
    • Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cellengaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-2498.
    • (2011) J Clin Oncol , vol.29 , pp. 2493-2498
    • Topp, M.S.1    Kufer, P.2    Gokbuget, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.